You must have an order with a minimum of $150.00 to place your order, your current order total is $0.00.
Peptide Education, Product Pillars, Research Protocols
Retatrutide: Complete Research Guide to the Triple Agonist Peptide
24
May
May
Research Use Only Notice: Retatrutide is a research peptide intended for in-vitro and animal research applications only. As of this writing, retatrutide is in late-stage clinical trials but has not received FDA approval. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.
Retatrutide is a 39-amino-acid synthetic peptide that simultaneously activates three receptors — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This makes retatrutide the first triple-receptor agonist to reach late-stage clinical trials, representing the next step in the evolution of incretin-based metabolic research compounds. Where semaglutide acts on one receptor and tirzepatide on two, retatrutide engages all three — producing body composition and metabolic effects in research that exceed both predecessors. This complete guide from the chemistry team at OPS Peptide Science walks through what retatrutide is, how the triple-agonist mechanism works, and how it compares to its single- and dual-agonist predecessors.
For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.
What Is Retatrutide?
Retatrutide is a synthetic peptide engineered to activate three distinct receptors involved in metabolic regulation: GLP-1R, GIPR, and the glucagon receptor. The triple-receptor approach extends the metabolic research effects of single-receptor (semaglutide) and dual-receptor (tirzepatide) predecessors by adding glucagon receptor activity — which contributes to additional metabolic and energy expenditure pathways.
Key facts about retatrutide:
- Chemical class — 39-amino-acid synthetic triple agonist (GLP-1 + GIP + glucagon receptor)
- Molecular weight — approximately 4731 Da
- Developer — Eli Lilly
- Half-life — approximately 6 days (supports weekly dosing)
- Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
- Regulatory status — in late-stage clinical trials (Phase 3); not yet FDA-approved
- Research-grade form — sold under research-use-only labeling for non-human research
Retatrutide sits at the leading edge of the GLP-1 family. The compound demonstrates an interesting research pattern — each generation of incretin agonist (single → dual → triple) has produced larger metabolic effects in research, suggesting that broader receptor coverage continues to deliver additive benefits.
Retatrutide Structure and Chemistry
Retatrutide builds on the engineering principles refined in semaglutide and tirzepatide:
- Glucagon-based peptide backbone — retatrutide is derived from glucagon, with modifications to give it activity at all three target receptors
- Strategic amino acid substitutions — multiple substitutions tune the receptor activity balance across GLP-1R, GIPR, and glucagon receptor
- Fatty acid chain attached — for albumin binding and extended half-life (similar strategy to semaglutide and tirzepatide)
- Aminoisobutyric acid substitutions — protect against DPP-4 enzymatic degradation
The triple-agonist design is technically demanding because each receptor has different binding requirements. Retatrutide achieves meaningful activity at all three through careful tuning of the binding interface — though it is a “biased” agonist with characteristic activity profiles at each receptor rather than equal potency.
How Retatrutide Works in Research (Triple Agonist Mechanism)
Retatrutide’s mechanism extends the dual-receptor approach of tirzepatide by adding glucagon receptor activity. Each receptor contributes distinct effects:
GLP-1 Receptor Component
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon suppression in pancreatic alpha cells
- Slowed gastric emptying
- Hypothalamic appetite reduction
GIP Receptor Component
- Additional insulin secretion enhancement (synergistic with GLP-1)
- Direct adipose tissue effects on lipid metabolism
- Centrally mediated appetite effects via brain GIP receptors
Glucagon Receptor Component (Unique to Retatrutide)
- Increased energy expenditure — glucagon receptor activity raises metabolic rate
- Hepatic glucose output modulation — increases glucose production in liver (counterbalanced by GLP-1’s insulin effects)
- Direct fatty acid oxidation effects in liver and muscle tissue
- Body composition effects from energy expenditure changes
The glucagon receptor component is what makes retatrutide unique. Adding glucagon agonism to GLP-1/GIP would seem counterproductive — glucagon normally raises blood glucose, which works against the insulin-promoting effects. But research has documented that retatrutide’s glucagon receptor activity produces useful metabolic effects (increased energy expenditure, fatty acid oxidation) without compromising the glucose-lowering effects of the GLP-1 component. The net result in research models is stronger body composition effects than either single or dual agonists deliver.
The published retatrutide research literature on PubMed documents these mechanisms in both pre-clinical and clinical-trial publications. Late-stage trials are tracked on ClinicalTrials.gov.
Retatrutide Research Applications
Metabolic Research
Research on insulin sensitivity, glucose tolerance, and broader metabolic biomarker panels. The triple-receptor mechanism produces stronger metabolic effects than dual or single agonists in head-to-head research data.
Body Composition Research
The largest research focus for retatrutide. Published research has documented body composition effects (lean mass, fat mass, distribution) that exceed both semaglutide and tirzepatide in comparable research designs. The energy expenditure mechanism from glucagon receptor activity is a key driver of this advantage.
Cardiovascular Research
Research on cardiovascular biomarkers, lipid profiles, and blood pressure trajectories. The combined receptor coverage produces broader cardiovascular research data than single-receptor approaches.
Liver Research
The glucagon receptor component makes retatrutide particularly active in liver research models. Hepatic glucose production, hepatic lipid content, and broader hepatic biology research have documented retatrutide effects beyond what GLP-1-only or dual-agonist compounds deliver.
Energy Expenditure Research
Unique to retatrutide among the GLP-1 family. Research has documented measurable increases in resting metabolic rate in animal models, attributed primarily to the glucagon receptor component. This mechanism opens research applications that single or dual agonists don’t address.
Retatrutide vs Semaglutide vs Tirzepatide
The three compounds represent successive generations of incretin agonist design. Direct comparison:
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor profile | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Amino acids | 31 | 39 | 39 |
| Half-life | ~7 days | ~5 days | ~6 days |
| FDA status | Approved | Approved | Phase 3 trials |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | None yet |
| Body composition effects in research | Strong (baseline) | Stronger | Strongest |
| Energy expenditure effects | Minimal | Minimal | Documented (glucagon-mediated) |
For research focused on body composition endpoints, retatrutide has become the most-cited compound in head-to-head studies. For glucose-regulation research, all three compounds remain heavily used depending on the specific design. For broader metabolic and energy expenditure research, retatrutide’s triple-receptor profile provides coverage no other compound delivers.
For deeper comparison context, see our companion guides on semaglutide and tirzepatide.
Retatrutide Dosing in Research Models
Research dosing for retatrutide follows patterns established for semaglutide and tirzepatide:
- Weekly subcutaneous administration — matches the 6-day half-life
- Dose titration — published research typically titrates over multiple weeks because the triple-receptor mechanism produces stronger effects that benefit from gradual adaptation
- Study durations 4-24 weeks — body composition and metabolic endpoints develop over multi-week protocols; some studies extend to longer durations
- Dose amounts — typically reported in mg per dose in clinical trial publications; animal research uses mg/kg
Research protocols should reference published methodology for the specific research model. Because retatrutide is newer than semaglutide and tirzepatide, the available protocol literature is smaller — though growing quickly as clinical trial data publishes.
Retatrutide Storage and Stability
Retatrutide stability follows the standard GLP-1 family profile:
| Storage Condition | Form | Stability Window |
|---|---|---|
| -80°C | Lyophilized powder | 3-5+ years |
| -20°C | Lyophilized powder | 18-24 months |
| 2-8°C | Lyophilized powder | 6-12 months |
| 2-8°C | Reconstituted in BAC water | 21-28 days |
| Room temperature | Lyophilized powder | 2-4 weeks for transit |
For practical storage protocols, see our guide on how long do peptides last at room temperature.
How to Identify Quality Research-Grade Retatrutide
Retatrutide’s complexity (39 amino acids, multiple modifications, fatty acid chain) makes purity verification especially important. Quality criteria:
- 99%+ HPLC-MS verified purity — synthesis of complex modified peptides produces measurable degradation products; high purity is essential
- Per-lot Certificate of Analysis — each batch independently tested with chromatographic profile
- Mass spectrometry identity confirmation — confirms molecular weight matches retatrutide (~4731 Da), distinguishing from related compounds
- Chain-of-custody documentation — traceable from manufacturer through fulfillment
- Properly lyophilized appearance — clean white cake at the bottom of the vial
- Research-use-only labeling — required by US regulations (retatrutide is not yet FDA-approved as a drug)
At OPS Peptide Science, every retatrutide vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.
Retatrutide Regulatory Status
Retatrutide occupies a unique position because it is not yet FDA-approved:
- Not FDA-approved — currently in Phase 3 clinical trials with Eli Lilly
- No prescription pathway in the US yet — no Mounjaro/Wegovy equivalent for retatrutide
- Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
- Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations
- WADA status — currently not specifically listed, though peptide hormones generally fall under WADA categories
- Not DEA-scheduled — no controlled substance status
Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug. The only legal pathway in the US currently is the research-chemical framework under research-use-only labeling. For the complete legal framework around research peptides, see our detailed guide on are peptides illegal.
FAQ
What is retatrutide?
Retatrutide is a 39-amino-acid synthetic triple-receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide is in late-stage clinical trials but not yet FDA-approved. It exists as a research-grade compound for in-vitro and animal research under research-use-only labeling.
How does retatrutide differ from semaglutide and tirzepatide?
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). Retatrutide activates three (GLP-1 + GIP + glucagon). The added glucagon receptor activity contributes energy expenditure effects that the other two compounds don’t produce. Research has documented stronger body composition effects with retatrutide than either predecessor in head-to-head studies.
Is retatrutide FDA-approved?
Not yet. Retatrutide is in Phase 3 clinical trials. If trial endpoints meet expectations, FDA approval could come in coming years. Currently, retatrutide exists only as a research chemical in the US, sold under research-use-only labeling for laboratory and animal study.
Why include glucagon receptor activity if glucagon raises blood sugar?
This is the interesting design question retatrutide addresses. Glucagon receptor activity increases energy expenditure and modulates fatty acid oxidation — useful for body composition and metabolic research. The glucose-raising effect of glucagon is counterbalanced by the strong glucose-lowering effects of the GLP-1 receptor component. Net effect in research: improved body composition without compromising glucose regulation.
How long does retatrutide stay in the body?
Retatrutide has a half-life of approximately 6 days, supporting weekly dosing in research models. Full clearance from the system takes 4-5 half-lives (about 3-4 weeks) after the last dose.
Is retatrutide legal in the US?
Research-grade retatrutide is legally sold in the US under research-use-only labeling for in-vitro and animal research. It is not FDA-approved for human use. Selling retatrutide for human consumption is not legal regardless of the molecule being identical to what’s being studied in clinical trials.
Where can I buy research-grade retatrutide?
Research-grade retatrutide is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade retatrutide.
Retatrutide represents the current leading edge of incretin agonist design — the first triple-receptor agonist in late-stage clinical trials. The combination of GLP-1, GIP, and glucagon receptor activity produces metabolic and body composition research effects beyond what dual or single-receptor compounds deliver. For researchers studying metabolic regulation, body composition, energy expenditure, or comparative GLP-1 family research, retatrutide is one of the most cited next-generation peptides in the modern catalog.
For research-grade retatrutide backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.
Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026
